{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:20:31Z","timestamp":1790803231513,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75595-4","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:34:03Z","timestamp":1784655243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vactosertib plus pembrolizumab in patients with non-microsatellite instability-high metastatic colorectal or gastric cancer: a multicenter, phase Ib\/IIa study"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-703X","authenticated-orcid":false,"given":"Keun-Wook","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6787-1503","authenticated-orcid":false,"given":"Joong Bae","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Iee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-7015","authenticated-orcid":false,"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-9074","authenticated-orcid":false,"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Sang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5886-3920","authenticated-orcid":false,"given":"Sun Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-9927","authenticated-orcid":false,"given":"Han Sang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2041-8104","authenticated-orcid":false,"given":"Minkyu","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saerom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-1997","authenticated-orcid":false,"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"75595_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"75595_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller, L. H. & Schrag, D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 325, 669\u2013685 (2021).","journal-title":"JAMA"},{"key":"75595_CR3","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med"},{"key":"75595_CR4","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3389\/fimmu.2019.01875","volume":"10","author":"ML Pinto","year":"2019","unstructured":"Pinto, M. L. et al. The two faces of tumor-associated macrophages and their clinical significance in colorectal cancer. Front Immunol. 10, 1875 (2019).","journal-title":"Front Immunol."},{"key":"75595_CR5","doi-asserted-by":"publisher","first-page":"101917","DOI":"10.1016\/j.eclinm.2023.101917","volume":"58","author":"M Fakih","year":"2023","unstructured":"Fakih, M. et al. Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine 58, 101917 (2023).","journal-title":"EClinicalMedicine"},{"key":"75595_CR6","doi-asserted-by":"publisher","first-page":"e2118416","DOI":"10.1001\/jamanetworkopen.2021.18416","volume":"4","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases. JAMA Netw. Open 4, e2118416 (2021).","journal-title":"JAMA Netw. Open"},{"key":"75595_CR7","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","volume":"30","author":"AJ Bullock","year":"2024","unstructured":"Bullock, A. J. et al. Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat. Med. 30, 2558\u20132567 (2024).","journal-title":"Nat. Med"},{"key":"75595_CR8","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.23.02736","volume":"42","author":"A Kawazoe","year":"2024","unstructured":"Kawazoe, A. et al. Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study. J. Clin. Oncol. 42, 2918\u20132927 (2024).","journal-title":"J. Clin. Oncol."},{"key":"75595_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med 21, 1350\u20131356 (2015).","journal-title":"Nat. Med"},{"key":"75595_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello, D. V. F. et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538\u2013543 (2018).","journal-title":"Nature"},{"key":"75595_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. TGF-beta signaling in health, disease, and therapeutics. Signal Transduct. Target Ther. 9, 61 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"75595_CR12","doi-asserted-by":"publisher","first-page":"e0191358","DOI":"10.1371\/journal.pone.0191358","volume":"13","author":"F Otegbeye","year":"2018","unstructured":"Otegbeye, F. et al. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One 13, e0191358 (2018).","journal-title":"PLoS One"},{"key":"75595_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to the exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"75595_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1021\/acsptsci.4c00374","volume":"8","author":"DVF Tauriello","year":"2025","unstructured":"Tauriello, D. V. F. et al. New potent inhibitor of transforming growth factor-beta (TGF\u03b2) signaling that is efficacious against microsatellite stable colorectal cancer metastasis in combination with immune checkpoint therapy in mice. ACS Pharm. Transl. Sci. 8, 97\u2013112 (2025).","journal-title":"ACS Pharm. Transl. Sci."},{"key":"75595_CR15","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research NComprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209 (2014).","DOI":"10.1038\/nature13480"},{"key":"75595_CR16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00262-020-02525-8","volume":"69","author":"YJ Zhou","year":"2020","unstructured":"Zhou, Y. J. et al. Identification and validation of tumor microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. Cancer Immunol. Immunother. 69, 1057\u20131069 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"75595_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu, R. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449\u2013456 (2015).","journal-title":"Nat. Med"},{"key":"75595_CR18","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","volume":"331","author":"WA Border","year":"1994","unstructured":"Border, W. A. & Noble, N. A. Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331, 1286\u20131292 (1994).","journal-title":"N. Engl. J. Med"},{"key":"75595_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1096\/fj.03-1273rev","volume":"18","author":"A Leask","year":"2004","unstructured":"Leask, A. & Abraham, D. J. TGF-beta signaling and the fibrotic response. FASEB J. 18, 816\u2013827 (2004).","journal-title":"FASEB J."},{"key":"75595_CR20","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1101\/gad.1653708","volume":"22","author":"J Andrae","year":"2008","unstructured":"Andrae, J., Gallini, R. & Betsholtz, C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22, 1276\u20131312 (2008).","journal-title":"Genes Dev."},{"key":"75595_CR21","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.immuni.2018.03.037","volume":"48","author":"K Ganesh","year":"2018","unstructured":"Ganesh, K. & Massague, J. TGF-\u03b2 Inhibition and Immunotherapy: Checkmate. Immunity 48, 626\u2013628 (2018).","journal-title":"Immunity"},{"key":"75595_CR22","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","volume":"29","author":"DC Guven","year":"2024","unstructured":"Guven, D. C. et al. The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review. Oncologist 29, e580\u2013e600 (2024).","journal-title":"Oncologist"},{"key":"75595_CR23","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/S0140-6736(25)02025-2","volume":"406","author":"JR Hecht","year":"2025","unstructured":"Hecht, J. R. et al. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet 406, 2360\u20132370 (2025).","journal-title":"Lancet"},{"key":"75595_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582\u2013598 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"75595_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303\u2013312 (2013).","journal-title":"Lancet"},{"key":"75595_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402, 41\u201353 (2023).","journal-title":"Lancet"},{"key":"75595_CR27","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N. Engl. J. Med"},{"key":"75595_CR28","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657\u20131667 (2023).","journal-title":"N. Engl. J. Med"},{"key":"75595_CR29","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/2326-6066.CIR-13-0207","volume":"2","author":"KH Young","year":"2014","unstructured":"Young, K. H. et al. TGF\u03b2 inhibition prior to hypofractionated radiation enhances efficacy in preclinical models. Cancer Immunol. Res 2, 1011\u20131022 (2014).","journal-title":"Cancer Immunol. Res"},{"key":"75595_CR30","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1200\/JCO.2017.35.15_suppl.3054","volume":"35","author":"JJ Lee","year":"2017","unstructured":"Lee, J. J. et al. Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer. J. Clin. Oncol. 35, 3054\u20133054 (2017).","journal-title":"J. Clin. Oncol."},{"key":"75595_CR31","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1200\/JCO.2016.34.15_suppl.3539","volume":"34","author":"NH Segal","year":"2016","unstructured":"Segal, N. H. et al. Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients. J. Clin. Oncol. 34, 3539\u20133539 (2016).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75595-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75595-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75595-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:56:21Z","timestamp":1787612181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75595-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75595"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75595-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Keun-Wook Lee (K.-W.L.) reports research funding to his institution for conducting clinical trials from MedPacto for the submitted work. He also reports research funding to his institution for conducting clinical trials from ALX Oncology, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, BeiGene, Bolt Biotherapeutics, Daiichi Sankyo, Elevar Therapeutics, Erasca, Exelixis, Genome & Company, GlaxoSmithKline, IgM Biosciences, Ildong Pharmaceutical, InventisBio, Jazz Pharmaceuticals, Leap Therapeutics, MacroGenics, Medicenna, Metafines, Merck KGaA, MSD, Ono Pharmaceutical, Panolos Bioscience, Roche, Seagen, Taiho Pharmaceutical, TRIO Oncology, Trishula Therapeutics, Wellmarker Bio, and Y-BIOLOGICS; consulting fees from AbbVie, Astellas Pharma, Daiichi Sankyo, Metafines, and MSD; honoraria for lectures or presentations from Astellas Pharma, Bayer, Daiichi Sankyo, Merck KGaA, and Sanofi\/Aventis; and an uncompensated relationship with ALX Oncology for participation on a data safety monitoring or advisory board. These activities are outside the submitted work unless otherwise specified. Young Suk Park (Y.S.P.), Joong Bae Ahn (J.B.A.), Young Iee Park (Y.I.P.), and Tae Won Kim (T.W.K.) report research funding to their institutions for conducting clinical trials from MedPacto for the submitted work. Ji-Won Kim (J.-W.K.) reports research support paid to his institution from Debiopharm, MitoImmune, Pyramid Biosciences, Adlai Nortye, Merck Sharp and Dohme, AstraZeneca, Lilly, and Aslan; and participation in a Data Safety Monitoring Board or Advisory Board for MedPacto and Lilly. Sun Young Kim (S.Y.K.) reports compensation for participating in advisory board meetings for Roche Korea, AstraZeneca, Natera, and Merck Sharp & Dohme Korea. Minkyu Heo (M.K.H.), Saerom Kim (S.K.), and Seong-Jin Kim (S.-J.K.) are employees of MedPacto, Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8925"}}